Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 7 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

404 Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment

  • Giuseppe Del Priore1
  • Markus D Lacher2
  • Miguel A Lopez-Lago3
  • William V Williams3
  • Suzanne Ostrand-Rosenberg4
4 affiliations
  1. 11 Obstetrics and Gynecology, Morehouse School of Medicine, Atlanta, Georgia, USA
  2. 2BriaPro Therapeutics Corp., Philadelphia, PA, USA
  3. 3BriaCell Therapeutics Corp., Philadelphia, PA, USA
  4. 4University of Utah, Huntsman Cancer Institute (HCI), Salt Lake City, UT, USA
Open at sourcePDFDOICite

Related

  1. Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)
    Christopher Bedding, Kate Absolom, Katarzyna Pogoda +14
    The BreastPeer-reviewedCC BY-NC-NDFull textGeneral biologyEpidemiology & public healthHAL
  2. Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer.
    Tsai-Yu Lin, Fu-Ling Chang, Shang-Ju Hsieh +7
    Translational oncologyPeer-reviewedCC BY-NC-NDFull textNeuroscienceEurope PMC
  3. Anti-PD-L1 antibody limits the survival of activated CAR T cells by disrupting the PD-L1/CD80 cis-heterodimer
    Sin-Syue Li, Markus Barden, Hong Pan +7
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  4. MHC-II+ G-MDSC expressing CD80, CD86, or ICOSL are associated with pro-inflammatory CD4+ T cells phenotypes in the lungs of lupus-prone mice
    Felipe R. Uribe, Sebastián A. Echeverría-Araya, Grabiel J. García-Velázquez +13
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJ
  5. Development of an Experimental Protocol for Combined Electroporation and Phototherapy Treatment Against Melanoma Cells
    Enrico Pierluigi Spugnini, Margherita Onofrj, Cosimo Assumma +1
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textSystems & synthetic biologyCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{priore2026development,
  title = {{404 Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment}},
  author = {Giuseppe Del Priore and Markus D Lacher and Miguel A Lopez-Lago and William V Williams and Suzanne Ostrand-Rosenberg},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0404},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0404},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 404 Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment
AU  - Giuseppe Del Priore
AU  - Markus D Lacher
AU  - Miguel A Lopez-Lago
AU  - William V Williams
AU  - Suzanne Ostrand-Rosenberg
PY  - 2026
DA  - 2026/11/05
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0404
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0404
SN  - 2051-1426
ER  -